Although an AR antagonist in combination with a PI3K/AKT pathway blocker curbed castration-resistant prostate cancer in Pten-null mice and human prostate tumor xenografts [16, 17], a combined regimen of these inhibitors showed low activity in a clinical trial [18]. Here, AKT1 is linked to prostate carcinoma.